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Widespread usage of antibiotics is a growing concern due to antibiotic resistance 
development in bacteria. This is due to common use of antibiotics in agricultural, 
livestock, and clinical usage. New strategies in drug development are necessary to 
combat the increasing resistance. We designed several motifs of sugar-modified 
nanoparticles to inhibit the biofilm formation of Pseudomonas aeruginosa. 
 P. aeruginosa is an opportunistic pathogenic bacterium that is responsible for 
common life-threatening infection in hospitals. This gram-negative opportunistic 
pathogenic bacterium infects hosts with compromised immune systems and contributes to 
complications in patients suffering from pneumonia, cystic fibrosis, and other immune 
compromising conditions. Biofilm formation from P. aeruginosa is used as an attack 
mechanism and adds to antibiotic resistance.  
P. aeruginosa lectins, LecA and LecB, are two sugar-binding proteins distinct in 
structure, binding preference and involvement of biofilm formation in this pathogen. 
Lectins, LecA and LecB, are specific to D-galactose, and L-fucose, respectively. 
Modifying the surface of our nanoparticle with the lectin-specific sugars achieves lectin 
binding selectivity, biofilm inhibition, and the ability to introduce antibiotic 
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The ongoing increase of antibiotic resistance represents a significant challenge to 
modern medicine [1–3]. Due to the widespread use of antibiotics in clinical and agricultural 
settings and the limited number of novel antibiotics being advanced into the market, the 
development of new treatment options for bacterial infection is of paramount importance.  
Pseudomonas aeruginosa represents one of the most significant gram-negative 
opportunistic pathogens involved in hospital-acquired infections. A report from the CDC-
NNIS (National Nosocomial Infections Surveillance, US Dept. of Health and Human 
Services) identifies P. aeruginosa as the second leading cause of pneumonia, the third 
leading cause of urinary tract infection, and the eighth most frequently isolated pathogen 
from the bloodstream [1–7]. Further, P. aeruginosa often causes lethal infections in cystic 
fibrosis and immunocompromised patients, for whom the formation of bacterial biofilms 
plays a central role in infection and resistance [8,9]. Given the rapidly increasing incidence 
of P. aeruginosa in the clinic coupled with the high levels of antibiotic resistance and 
production of copious biofilms often found with this pathogen, the development of novel 
treatment strategies is imperative [10–12].  
In P. aeruginosa, biofilm formation is regulated by a cell-cell communication 
mechanism known as quorum sensing, which is mediated by bacterial cell-surface lectins 
involved in cellular adhesion [13,14]. Specifically, the galactose-binding lectin LecA (PA-
2 
 
IL) and the fucose-binding lectin LecB (PA-IIL) have prominent roles in bacterial 
virulence, cellular adhesion, tissue colonization, and/or invasion and biofilm formation 
[15–17]. Several recent reports have evaluated approaches to inhibit the virulence and/or 
biofilm formation in P. aeruginosa through inhibition of quorum sensing or lectin binding. 
Notable about these anti-virulence approaches is the potential they possess for species-
selectivity by targeting the inhibition of cellular processes in a manner that uniquely 
inhibits the virulence and/or infectivity of P. aeruginosa. Accordingly, treatments 
developed for these P. aeruginosa-specific targets are anticipated to have a lower impact 
on the beneficial commensal bacterial population and may possibly exhibit reduced 
pressure for the development of antibiotic resistance. 
Prior studies developing inhibitors of P. aeruginosa LecA have described mono-valent 
and multi-valent inhibitors of this lectin and have characterized the positive effect on 
inhibitor avidity through multivalency [12,17]. We rationalized that we might achieve 
similar high binding avidity for LecA using a polymeric nanoparticle with multiple copies 
of a LecA ligand on the surface of the particle. Further, we recognized that unlike 
dendrimeric or small molecule inhibitors of LecA, the surface-modified polymeric 
nanoparticles that we aimed to prepare would be capable of encapsulating a fluorescent or 
drug molecule within their lipophilic core, potentially enabling future applications in 
targeted antibiotic drug delivery or fluorescent labeling for diagnostic applications. Here 
we report our findings on the development and anti-biofilm properties of a series of LecA-





2.1 Synthesis of galactose-modified di-block do-polymer. The D-galactose-
modified di-block co-polymer required for nanoparticle assembly (5) was prepared from 
β-D-galactose pentaacetate in six steps (Scheme 1). In short, β-D-galactose pentaacetate 
(1) was coupled to benzyl 4-hydroxybenzoate (2) to provide ester 3. Removal of the benzyl 
protecting group by hydrogenolysis provided carboxylic acid 4, which was coupled to 6.6 
kD amine terminated di-block co-polymer [18]. Removal of the acetate protecting groups 
on the sugar preceded purification of the sugar-modified polymer 1 by dialysis using a 5 
kD molecular weight cutoff (MWCO) membrane. The resulting dialyzed D-galactose-
modified polymer (5) was concentrated by lyophilization and the resulting white powder 
was characterized by NMR, IR, and MALDI-MS. Having prepared the requisite galactose-






Scheme 1. Synthesis of modified di-block co-polymer for nanoparticle assembly. 




2.2 Nanoparticle preparation. Nanoparticles were prepared by flash 
nanoprecipitation using established methods [18,19] with varying ratios of the modified D-
galactose polymer and unmodified di-block co-polymer to provide 100%-, 50%-, and 25%-
surface-modified nanoparticles using the parameters described in Table 1. All 

























































































Data represent the mean with error described as the standard error of means of at least three independent 
preparations of the particles, each with three instrumental replicates. 2 Polydispersity Index (PDI) = (standard 




All D-galactose nanoparticle (Gal-NP) suspensions were prepared as 0.02 mg/mL 
solutions in water and characterized in terms of particle diameters (Figure 1) and 
polydispersity indexes (PDI). The particles prepared are described in this manuscript based 
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on the relative concentration of surface-modified D-galactose to enable direct comparison 
of the effect of the prepared nanoparticles on lectin binding and biofilm inhibition to free 
D-galactose, used as a control. Having prepared a series of galactose-modified polymeric 





Figure 1. Schematic showing assembly of D-galactose surface-modified polymeric 
nanoparticles. B. Particle size distribution of prepared polymeric nanoparticles. Each data 
point represents the average particle diameter of an independent formulation. C. 




2.3 Inhibition of LecA-mediated hemagglutination. The binding affinity of the 
modified nanoparticles for the P. aeruginosa lectin LecA was evaluated using a 
hemagglutination assay [20]. Briefly, this assay measures the inhibition of LecA-induced 
hemagglutination of rabbit erythrocytes by comparison with D-galactose as a control. The 
exceptional effect of ligand multivalency was noted with the 100%- and 50%-modified NP 
samples, which were evaluated based on the concentration of galactose on the surface of 
the nanoparticles (Table 2). The strongest effect was observed with the 50%-modified Gal-
NP, showing a 992-fold increase in relative potency compared with free galactose. The 
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100%-modified Gal-NP samples inhibited hemagglutination when modified with 
concentrations above 6.31μM of galactose, representing a 495-fold increase in potency 
relative to free galactose. The 25%-modified NP showed no inhibition of hemagglutination 
up to the highest surface concentration of D-galactose evaluated (2.36 μM). A control 
100%-mannose-modified polymeric NP (37.9 μM mannose) showed no inhibition of 
hemagglutination, supporting the hypothesis that the inhibition of LecA is mediated by 




















Inhibition of P. aeruginosa LecA-induced hemagglutination. 
 
 
MIC = minimal inhibitory concentration for the hemagglutination assay following two-fold serial 
dilutions of tested compounds; the MIC corresponds to the highest dilution resulting in the 
inhibition of LecA-induced hemagglutination based on the relative sugar concentration. 2 No 
inhibition of hemagglutination up to highest concentration evaluated (galactose concentration of 
2.36μM). 3 No inhibition of hemagglutination up to highest concentration evaluated (maltose 




The high potency of the particles in this assay is consistent with previous reports of 
high avidity LecA binding using galactose modified dendrimers [12,20]. It is noted that the 
% modification of the particle leads to maximal inhibition with the 50%-sugar-modified 
particles. Particles with lower galactose modification (25%-modified) showed no 
inhibition of hemagglutination at the highest concentrations tested ([galactose] = 2.36 μM) 
and those with higher modification (100%-modified) had a two-fold higher MIC. It is 
possible that a sugar concentration greater than 2.36 μM on the nanoparticles is required 
for high avidity; however, higher sugar concentrations as would be present in the 100%-


























2.4 Inhibition of P. aeruginosa PAO1 biofilm formation. Having identified that our 
100%- and 50%-D-galactose-modified polymeric nanoparticles are effective at inhibiting 
LecA-induced hemagglutination, we evaluated their effect on bacterial biofilm formation 
using the well-established crystal violet assay [21,22]. Briefly, P. aeruginosa strain PAO1 
was inoculated in 96-well plates in the presence of varying concentrations of Gal-NP, 
controls, and/or free D-galactose. Biofilm formation was evaluated after 24 h by removing 
non-adherent bacteria, crystal violet staining of the adherent cells, and determination of 
absorbance at 550nm. In this assay, we observed a potent dose-dependent inhibition of 
biofilm formation with our surface-modified Gal-NP samples (Figure 2). Inhibition of 
biofilm formation was noted at D-galactose concentrations above 12.6 μM in the 100%-
surface-modified nanoparticle samples and at concentrations above 6.3 μM in the 50%-
surface-modified series. Again, the significance of ligand valency is evident, as free D-





Figure 2. Inhibition of P. aeruginosa PAO1 biofilm formation based on the crystal violet 
assay. Surface-modified Gal-NP samples are described based on the % surface 
modification and the relative concentration of D-galactose on the nanoparticle surface. 
All data points are described as the mean of triplicate measurements with error bars 
representing the standard deviation. 
 
 
2.5 Evaluation of growth inhibition.  No significant inhibition of growth was noted 
at any of the nanoparticle concentrations evaluated in our biofilm inhibition assay. The 
absence of growth inhibition supports the hypothesis that that nanoparticle-LecA binding 

































































































































Figure 3. Evaluation of P. aeruginosa PAO1 growth by monitoring OD600 with 100%-D-
galactose-surface-modified nanoparticles (A) and 50%-D-galactose-surface-modified 
nanoparticles (B). No significant growth inhibition is observed with 100%-modified Gal-
NP at concentrations below 37.9 μM or with 50%-modified Gal-NP at concentrations 
below 18.9 μM. Growth inhibition was noted at concentrations two-fold higher than those 
employed in the biofilm inhibition assays (100% Gal-NP at 75.8 μM and 50% Gal-NP at 
37.8 μM). Error bars represent standard deviation of triplicate analysis. 
 
2.6 Evaluation of biofilm inhibition and morphology. We subsequently evaluated 
the inhibition of biofilm formation in the hyper-virulent isolate of P. aeruginosa PA14 by 
fluorescent confocal microscopy. Briefly, 24-h biofilms were prepared by inoculation of 
PA14-GFP [23] into Luria broth (LB) containing the appropriate treatments or controls. 
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The resulting biofilm was then evaluated by fluorescent confocal microscopy. In this 
experiment, we observed clear changes in the overall biomass and average biofilm 
thickness of the Gal-NP-treated samples, consistent with our observations in the crystal 
violet assay. Additionally, in this experiment, we captured distinct changes in the 
morphology of the biofilm that are evident at sub-inhibitory concentrations. These 
observations further support the inhibition of cellular adhesion by D-galactose surface 
modified nanoparticles. 
Within the 100%- and 50%-surface-modified samples of nanoparticles we observed 
the inhibition of biofilm formation based on evaluation of biofilm biomass and average 
biofilm thickness at concentrations above ~19.5 μM; however, effects on biofilm 
morphology were apparent at even lower concentrations (Figure 4). The slightly higher 
concentrations required to inhibit biofilm formation in the hypervirulent PA14 strain, 
compared with our crystal violet assay with PAO1, are consistent with previous studies of 
this bacteria [24,25]. In this assay, we observed no inhibition of biofilm formation by free 
D-galactose, even at concentrations of 48,000 μM (Figures 4 and 5). Visual inspection of 
the images collected (Figure 4 and Supporting Information) show that with increasing 
concentration of D-galactose-modified nanoparticles the biofilm begins to display 
increasing numbers of spaces within the biofilm structure (Figure 4, panel A vs. B vs. D). 
This effect is consistent with the anticipated inhibition of cellular adhesion achieved by 





Figure 4. Fluorescent confocal microscopy evaluation of P. aeruginosa PA-14 biofilms. 
Samples treated with Gal-NP show inhibition of biofilm formation. The biofilm 
morphology at sub-inhibitory concentrations of Gal-NP (e.g. 100%-modified at 9.75 μM) 
shows evidence of anti-adhesive properties of Gal-NP, which increase with higher 




Quantification of the biomass and average biofilm thickness of the confocal images 
using the program Comstat2 shows dose-dependent inhibition of biofilm formation 
(Figures 5A and B). Most striking is the quantification of biofilm surface area as a function 
of volume. This calculation nominally provides a measure of the quantity/size of spaces 
within the biofilm structure. Consistent with the hypothesis that Gal-NP inhibit cellular 
adhesion without inhibiting growth/viability, we observe a dose-dependent increase in the 





Figure 5. Quantification of (a) biofilm total biomass, (b) average biofilm thickness, and 
(c) biofilm surface area/volume from fluorescent confocal microscopy analysis. Images 
were analyzed using Comstat2 processing of duplicate analysis and are reported as means 




Recently, significant interest has been directed at the development of antivirulence 
strategies to combat infectious diseases. As these approaches do not directly impact 
viability or growth, a reduced selective pressure for resistance is anticipated. For the 
inhibition of biofilm formation, many antivirulence agents being developed focus on the 
inhibition of the quorum-sensing signaling pathways [14,24,26] or inhibition of bacterial 
adhesion [20,27,28]. Bacterial lectins are implicated in key roles in bacterial adhesion and 
biofilm formation, including the lectins LecA and LecB, which play a prominent role in P. 
aeruginosa. Here we report the development of the first LecA-targeted surface-modified 
polymeric nanoparticle. The particles prepared showed high avidity for LecA in the 
inhibition of hemagglutination, consistent with a beneficial effect of multivalent display of 
the lectin ligand on the particle surface. We observed greater than 100-fold enhancement 
in potency, compared with free D-galactose in the assay with 100%- and 50%-surface 
modified D-galactose nanoparticles. Further, we demonstrated potent inhibition of P. 
aeruginosa biofilm formation in the presence of these surface-modified nanoparticles, 
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demonstrating the anti-virulence potential of these novel inhibitors of the P. aeruginosa 
lectin LecA. 
Previous studies have shown that LecA is cytotoxic [29] and has an important role in 
cellular adhesion and lung infection [17]. LecA is a homotetramer and displays specificity 
for galactose. Due to the high affinity of LecA for galactose, numerous multivalent and 
dendrimer structures have been developed as inhibitors of this protein [12,20,27,28]. The 
significant increase in LecA binding potency noted in these dendrimeric constructs was 
captured in the polymeric nanoparticles in this study, which were found to be potent 
inhibitors of LecA-induced hemagglutination and bacterial biofilm formation.  
Notably, the assembly of nanoparticles as highly multivalent scaffolds for lectin 
binding avoids many of the synthetic challenges of dendrimer synthesis [30,31]. 
Accordingly, we anticipate that the application of polymeric nanoparticles to achieve the 
high lectin-binding potency observed with dendrimers, as demonstrated here, will serve as 
a powerful and useful complimentary approach for the inhibition of bacterial lectins and 
other cell-surface receptors. Self-assembly of sugar-modified di-block co-polymers using 
flash nanoprecipitation [19] further enables ready introduction of multiple different ligands 
to enable targeting multiple biological targets with a single nanoparticle construct, further 
enhancing biological activity. 
Polymeric nanoparticles have been extensively studied in several medical 
technologies, especially in the area of drug delivery [11,32–37]. The advantages of 
improved pharmacokinetics and therapeutic properties, including mucus penetration [38], 
continue to stimulate interest in the field. As demonstrated here, surface modification of 
the nanoparticle enables targeting of the constructs to the bacterial pathogens of interest, 
15 
 
potentially enabling species-specific delivery of drugs, diagnostic reagents, or other small 
molecules.  
4. Conclusion 
In conclusion, polymeric nanoparticles synthetically modified to provide surface 
display of conjugated D-galactose bind to the P. aeruginosa lectin LecA with high potency. 
The benefit of high ligand valency to achieve high avidity lectin binding is efficiently 
realized in these constructs. Several of the polymeric nanoparticles were found to inhibit 
biofilm formation in a manner consistent with an antivirulence (anti-adhesion) mechanism 
of action, providing a new and powerful technology for species-specific inhibition of 













Synthesis of Multivalent Galactose Modified Polymers 
5. Introduction  
Our first-generation NPs, mono-modified galactose NPs, provided strong 
evidence to support the ability to combat P. aeruginosa, and antibiotic resistance. 
Observation of polymer-linked galactose nanoparticles displayed a notable effect, where 
50%-modified Gal-NP showed a 992-fold increase in relative potency compared with 
free galactose. Observation of no activity above 38,000 µM of free galactose could be 
contrasted to the 38 µM of galactose on the surface of nanoparticles. This provided 
evidence that localization due to surface modification is necessary for galactose to have 
LecA activity and that free galactose alone would not be enough. Furthermore, 
examination into unmodified nanoparticles and mannose surface-modified nanoparticles 
provided no activity against P. aeruginosa.  
The next step of our project, following the success of our first-generation mono-
modified galactose nanoparticles, was to shift direction towards improving our 
nanoparticles by increasing the valency of galactose per unit polymer. For instance, we 
hypothesized that a di-valent galactose, where two galactoses are attached per unit 
polymer, would be more active than our previous mono-galactose NP modification. 
Further, we anticipate that tetra-modified galactose nanoparticles, where the surface of 
the nanoparticles has four times the concentration of galactose than our first-generation 
mono-galactose modified nanoparticles will provide even higher activity. To test this 
hypothesis, we designed, evaluated and optimized a series of synthetic schemes involving 
17 
 
lysine modification, cyanic chloride, and other linker materials to achieve multivalent 
galactose-polymers. 
6. Results 
 6.1 Synthesis of mono-boc benzyl-diamine linker. Lysine was chosen to be a 
linking molecule due to its functional group identity. Two amines and a carboxylic acid 
are available for modification. We recognized that attaching galactose molecules to 
lysine’s amines and using the acid on lysine for linkage to the polymer to give a di-valent 
galactose functionalized nanoparticle. Unfortunately, direct coupling of the modified 
lysine to the polymer through direct reaction of the carboxylic acid on lysine proved 
difficult. Optimization of synthetic route lead to addition of a diamine linker, which 
would provide ease in coupling of the lysine carboxylic acid to our di-block copolymer. 
This diamine linker, was optimized to be protected at one single amine using one Boc 
(tert-Butyloxycarbonyl) protection group (Scheme 2). 
  
 







Scheme 3. Synthesis of Fmoc and Boc protected lysine-diamine-linker. 
 
 
6.2 Synthesis of bis-galactose PS-PEG. Lysine-Galactose coupling was achieved 
after trials with a series of coupling reagents and conditions. The coupling of bis-Fmoc 
(Fluorenylmethyloxycarbonyl) amine protection on lysine and Boc protection for diamine 
linkage proved to be the most effective method to prepare lysine for sugar-polymer 
couplings (Scheme 3). Specifically, HATU coupling followed by direct product 
precipitation was found to be best for product yield (Table 3). While an isolated yield of 
approximately 35% is non-ideal for this reaction, it appears that the majority of the 
material lost in this reaction is due to the difficulty in product purification/isolation. 
Direct precipitation provides the highest yield for this process and as starting materials 















(%)  Work-Up/Purification 
BOP 14 < 1 standard 
PyBOP 14 < 1 standard 
HATU 14 < 1 standard 
BOP 3 26 standard 
PyBOP 4 10 standard 
HATU 2 24 standard 
HATU 2 35 
direct product 
precipitation 
Note. Coupling reagents used to bind galactose and lysine via diamine linker. Reaction 
was performed as an amide coupling with HATU at 35% yield.  
 
Having prepared the required lysine with our polymer linker in place, we 
turned our attention to the removal of the Fmoc protecting groups and incorporation 
of our required galactose sugars on lysine. Fmoc deprotection with DBU (1,8-
Diazabicyclo(5.4.0)undec-7-ene)  followed by ether trituration precipitated free-amine 
lysine. The crude product was immediately exposed to previously galactose 
derivatives for PyBop assisted amide coupling (Scheme 4). Following purification, we 
were pleased to confirm the structure of the desired bis-galactose modified lysine 
through NMR analysis (Figure 6 and Supporting Information). Some key signals in 
the 1H-NMR spectra (Figure 6), include the presence of 4 distinct methyl singlets at 
~2 ppm which correspond to the four distinct acetate groups on the coupled galactose 
fragments and the methyl singlet at ~1.2 ppm which corresponds to the Boc-protecting 
group on the linker attached to lysine. Additionally, integration of the acetate groups 
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on the sugar to the Boc group on lysine is 6:9 which is consistent with the desired bis-
galactose product. 




Scheme 4. Synthesis of bis-galactose modified lysine from bis-fmoc lysine. (A) 
Synthesis of galactose linker for bis-modification. 
 
Having prepared the required bis-galactose modified lysine, one pot coupling 
to the 6.6kD PS-PEG-OH diblock co-polymer and subsequent acetate deprotection 
was then attempted (Scheme 4). Success in coupling was achieved with 83% 
conversion, where unmodified 6.6kD PS-PEG-OH and our desired modified polymer 
have, to date, proven to be inseparable. While we continue to seek to optimize this 
process to achieve 100% conversion, the mixture of modified and unmodified polymer 
does not prohibit our NP assembly, it simply limits the maximum level of surface 




Scheme 5. Synthesis of galactose-modified lysine to PS-PEG 
 
Confirmation of products and determination of % polymer modification was 
achieved with NMR and mass spectroscopy. The final bis-galactose polymer was too 
high molecular weight for standard LC-MS measurement. Instead, our products were 
analyzed by MALDI-MS using methods that would measure compounds of 6kDa to 
10kDa in accuracy. It should be noted that the polydispersity of the polymer 
complicates the analysis significantly by providing a broad peak in the MALDI-MS, 
consistent with prior studies.  
Figure 7. MALDI-MS comparison of 83% modification of galactose per unit polymer 





To provide a measure of the % polymer modification the delta, or difference 
between the size seen in the MALDI-MS unmodified and modified polymer peak was 
measured. This delta value represents a molecular weight difference of 711.141 g/mol 
between unmodified PS-PEG (6.6kDa) and bis-galactose modified PS-PEG. This can 
be compared to the theoretical delta value calculated to be 856.88 g/mol to provide our 
approximation of 83% modification of the polymer. Moreover, MALDI-MS allows 
for more accurate measurement of our PS-PEG (nominally 6.6kDa per commercial 
vendor (Polymer Source Inc.) specifications), where unmodified PS-PEG was found 
to be polydisperse and centered at 6398.314 g/mol by our MALDI-MS measurements. 
Importantly, the discrepancy between the predicted average mass of the unmodified 
polymer at 6.6kD and the observed mass of ~6.4kD would not change our calculation 
of % sugar modification as this is achieved by determination of a delta value prior and 
after conjugation as described above. 
6.3 Evaluation of biological activity with 60% modified galactose 
nanoparticles.    Our second-generation nanoparticles or, bis-galactose modified 
nanoparticles, were evaluated for bacterial biofilm formation using crystal violet assay 
procedures previously described in our first-generation mono-modified nanoparticle. 
This assay observed a potent dose-dependent inhibition of biofilm formation with our 
surface-modified Gal-nanoparticle samples up to 60% modification (Figure 8). 
Inhibition of biofilm formation was noted at D-galactose concentrations above 2.29 
μM in the 60%-surface-modified nanoparticle samples. To confirm that the biofilm 
inhibitory activity observed was not due to growth inhibition by the nanoparticle 
samples evaluated, we collected growth curve data for PAO1 by monitoring OD600 
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(Figure 9). We determined that at higher concentrations, above 2.29 μM, inhibition of 
growth would occur. The resulting potency for biofilm inhibitory effect of our 60% 
bis-galactose-modified nanoparticles proved to be about 33 times more potent than our 
previously described 100% mono-galactose-modified nanoparticles, which achieved 
inhibition at concentrations as high as 75.8 μM.   
 
 
Figure 8.  Crystal Violet endpoint assay with P. aeruginosa strain PAO1 and 60% 
modified bis-galactose-polymer nanoparticles at a 2-fold dilution at 48 hours. All data 
points are described as the mean of triplicate measurements with error bars representing 







Figure 9. Growth inhibition assay with p. aeruginosa strain PAO1 and concentration 
curve of 60% modified bis-galactose-polymer nanoparticles at a 2-fold dilution. All data 
points are described as the mean of triplicate measurements with error bars representing 
the standard deviation.  
 
 6.4 Synthesis of tetra-galactose modified PS-PEG. A synthetic route was 
proposed in order to couple four galactose sugars per unit PS-PEG.  Our previously 
used sugar, bis-galactose-lysine-diamine, could be added twice to a linker with two 
available sites. This would allow for two of our lysine-sugars to be added to one-unit 
PS-PEG, thus having four galactose sugars per polymer. A linker material was 




    




6.5 Confirmation of di-chlorotriazine PS-PEG. Synthesis of TCT-PS-PEG 
presented the first challenge to achieving tetra-galactose modification. A slew of 
optimization reactions with TCT and a test polymer, Diethylene Glycol Monomethyl 
Ether, were performed in order to achieve the di-chlorotriazine PS-PEG product. Under 
mildly basic condition for 18hrs eludes the di-chlorotriazine PS-PEG product. 
Confirmation of product was optimized by examining di-chlorotriazine Diethylene 
Glycol Monomethyl Ether products due to their significantly reduced molecular weight. 
by examining Carbon NMR spectrums, we concluded a shift from the starting material, 
TCT, single peak at δ172, which are for the 3 carbons in TCT. When the C-NMR of 
product is examined, there is one new peak that shows up at δ171. The new peak is 
shorter and lower providing to us that Diethylene Glycol Monomethyl Ether was bound 
only once to TCT. We can apply this interpretation to other polymers coupling to TCT 




Figure 10. H-NMR of unreacted diethylene glycol monomethyl ether (Left), reacted 
diethylene glycol monomethyl ether with TCT (Right) 
 
The 6.6kDa PS-PEG coupling to TCT was achieved using reaction conditions 
optimized with Diethylene Glycol Monomethyl Ether with TCT. As expected, we could 
conclude our product was achieved by C-NMR by the difference of carbon peaks at δ172 
and δ171. 
 
Scheme 7. Mechanism of PS-PEG-OH (6.6kD) coupling to TCT. 
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Figure 11. C-NMR of TCT reacted with PS-Peg-OH (6.6kD), where peaks at δ172 and 
δ171 represent confirmation of coupling by polar changes in the molecule following PS-
PEG attachment. 
 
 6.6 Synthesis of tetra galactose-modified di-block co-polymer. In order to 
make the final product, the bis-galactose-lysine-diamine needed to be reacted with TCT 
at the other available sites (chlorine leaving groups) on TCT. This step proved to be the 
most challenging in terms of reaction success and qualification. Liturature on the subject 
of displacing TCT’s chlorines proved to be trivial [45]. However, many cases in liturature 
seeked to couple low molecular weight molecules to TCT [45]. Our high molecular 
weight 6.6kDa PS-PEG and bulky bis-galactose-lysine-diamine would prove to likely add 
to the complication of this coupling. Several attempts to achieve coupling at 80°C were 
attempted without product. MALDI-MS was used to confirm products, similaraly to how 
we confirmed our bis-gal-PS-PEG products. In solution, tempurature is thought to 
increase reactivity at the TCT sites. However, by increasing temperature the polymer 
could begin to rotatate around itself, which might prevent the lysine from binding to the 
polymer. Our solution to this problem was to attempt this reaction in a microwave reactor 
at 70°C.  It was anticipated that using a microwave would assist in a better distributed 
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heating of the reaction opposed to traditional oil bath heating. Microwave conditions also 
allowed to reduce reaction times from 2 days to 2 hours (Scheme 7). This change 
provided product as confirmed by MALDI-MS (Figure 12). 
 
 
Figure 12. MALDI-MS of TCT tetra-modified galctose product (blue-green) and the 





Finalizing the sythnesis required acetate deprotection of our fully coupled product. 
To carryout this reaction we attempted basic conditions in NaOMe/MeOH. The resuting 
product lead to decoupling of poylmer from our TCT-lysine-sugar complex. 
Unfortunently, reproducablity of this product was unsuccessful due to instumental 
problems and our TCT nanoparticles are still under development. 
 
 






               Bis-modification of PS-PEG with galactose provided an increase of potency at 
60% modification eluding the possibilities of future bis modified polymeric nanoparticles 
of up to 100% modification. However, synthetic goals are challenged by increasing 
modification with tetra-modified PS-PEG with galactose. A new synthetic scheme using 
a lysine-on-lysine was developed due to synthetic challenges seen in our TCT preparation 
(Scheme 8). Lysine, would act as a TCT substitute due to its function to have 3 sites of 
coupling. Moreover, discovery in how to couple lysine had already been optimized in our 
previous analogs with coupling of a benzyl-diamine moiety. Preliminary work on this 
synthetic route provided crude products.  
8. Conclusion 
              The results of our 60% bis-galactose modified nanoparticles provided a 33-fold 
increase in potency compared to our first generation nanoparticles in preliminary 
bacterial assay studies. These results suggest that further modification would provide 
substantially more potent nanoparticles against P. aeruginosa. Further bacterial assay 
studies are expected to provide decreased toxicity and improved biofilm growth 
inhibition. However, synthetic challenges have proven to be a crux before determining 







Synthesis of Fucose Modified Polymers 
9. Introduction 
 Our focus on D-galactose modified sugars provided strong evidence to support 
their binding and affinity to LecA. However, biofilm formation is also regulated by LecB. 
LecB binding had yet been evaluated due to lectin binding interaction to L-fucose. To 
examine LecB specificity, L-fucose surfaced-modified NPs were necessary for our 
objectives. We hypothesized a similar scaffold of sugar-polymer to be a potent molecule 
for interaction upon NP formation. These scaffolds, include both Lectin B specify and 
increased sugar valency. In LecA targeted, we modified each block copolymer with a 
single sugar molecule. In LecB targeted, we aimed to modify each polymer with two 
sugars using lysine as a linking molecule. 
10. Results 
10.1 Synthesis of bis fucose-modified di-block co-polymer using lysine. 
Designing LecB targeted NPs began with an isoxazole linker synthesis (Scheme 9). This 
linker was chosen from a number of different linkers that provide increased affinity for 
LecB when conjugated with fucose [20]. A linker also provides us with opportunity to 
terminate our linker-sugar with a carboxylic acid. This functionality allows for easy 
amide formation for our suggested bis or tetra modified species. Specifically, we examine 
amide formation on amines present on lysine. Lysine, having two amines, could be 




Scheme 9. Synthesis of LecB linker synthesis starting with ethyl glyoxylate. 
 
Ethyl glyoxylate is reacted with hydroxylamine in preparation for cyclization at 
seventy-three percent yield.  The key moiety in this linker synthesis is an isoxazole ring, 
which likely contributes to the increased affinity seen in previous studies [46]. Prior to 
cyclization, N-chlorosuccinimide is reacted on the alkene giving it a chlorine necessary 
for its leaving group probability upon reaction with an alkyne in a Diels-Alder-like 
cyclization. This step is performed at 82 percent yield. It was suggested at this point 
addition of sugar and subsequent reduction of the ethyl ester would be achieved, 
however, this led to degradation, particularly upon LiOH reduction (Scheme 10).  
 
 
Scheme 10. Synthesis of LecB linker coupling with L-Fucose. 
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To rework the synthesis, we proposed to protect the alcohol on the linker 
molecule and immediately perform reduction of the ethyl ester before addition of fucose. 
This would reverse our couplings, meaning we will couple the acid to lysine prior to 
sugar coupling (fig mole). TBDPS (tert-Butyldiphenylsilyl) protection was used, since it 
contained two large aromatic rings that could be easily detected by UV supported flash 
purification. Synthesis was achieved using our previous reaction, however, before 
cyclization with propargyl alcohol, the hydroxyl was protected with TBDPS. Following 
reduction of the ethyl ester, coupling to lysine was performed with HATU reagent using 
our diamine terminated lysine following our previous preparation. Unfortunately, upon 
TBDPS deprotection with TBAF degradation occurs. Several workarounds were 
examined including differing acid deprotection reagents and modifying protection 
groups, but none provided product.  
 
 




It was determined that our isoxazole linker could be replaced by another linker; 
one that we were familiar with in our galactose synthesis. By including our pervious 
hydroxyl benzyl acid linker as a LecB linker we can still achieve increased potency in 
fucose-lectin binding. We completed synthesis as per our previous procedure, but now 
with L-fucose instead of D-Galactose (Scheme 12).  
 
 
Scheme 12. Revised synthesis of LecB linker synthesis starting with benzyl benzoate.  
 
For our LecB targeted nanoparticles, we took our focus directly to sis-modified 
nanoparticles. Our discovery into a reproducible lysine product would provide to useful 
to bind our modified fucose to our block co-polymer. Following the synthesis used in 
LecA, we were able to achieve 100% modified nanoparticles with bis-fucose. This also 
allowed us insight into the multi-step process, specifically, we determined several issues 
regarding our final steps. It was determined that in some cases severe degradation of the 
molecule occurs after sodium hydroxide deprotection of acetate groups on our sugars.  In 
this case, where we achieved product at 100% modification, where conditions involved 
the removal of the atmosphere from exposer to the reaction vessel. MALDI-MS 
confirmed that the product had been achieved by providing a difference or delta value 
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between the maximum intensity of the un-modified PS-PEG (6.6 kDa) and the bis-fucose 
modified PS-PEG (6.6kDa) at a value of 871.054 g/mol. (Figure 13). This can be 
compared to the calculated molecular weight, 866.92 g/mol, of our bis-fucose benzyl-
diamine lysine, which accounts for the only difference (delta) between the two 
compounds. This comparison confirms that we successfully modified PS-PEG (6.6kDa) 
in ~100% conversion.  
 
 
Scheme 13. Mechanism of LecB fucose-linker coupling with lysine and subsequent 




Figure 13. MALDI-MS of 100% modification of PS-PEG (6.6 kDa) with bis-fucose 
lysine (maroon) compared to non-modified PS-PEG (6.6kDa). 
 
10.2 Nanoparticle precipitation of bis-modified fucose polymers. Nanoparticle 
formation was preformed using a mixing block to precipitate nanoparticles of fucose 
surface modification at 100%, 50%, 25% and 0%. This is achieved using mixtures of 
modified PS-PEG and un-modified PS-PEG at the corresponding ratios. Procedure for 
precipitation is followed as conducted in section 2.2. In addition to section 2.2, the 
precipitated nanoparticles undergo a 30-minute desiccation under reduced pressure on a 
rotary evaporator followed by a two-hour desiccation in a chamber under reduced 
pressure to remove any THF present in the sample from flash precipitation. This process 
ensures that the nanoparticle solution will not have THF present during bacterial assay 
studies, which could affect the outcome due to toxicity. Nanoparticles are then analyzed 
for particle size and polydispersity by dynamic light scattering (DLS) (Figure 14). DLS 





Figure 14. Dynamic light Scattering data for bis-fucose surface modified nanoparticles at 
100%-0% surface modification. 
 
10.3 Evaluation of biological activity with bis fucose-modified nanoparticles. 
Biological activity of Fucose modified nanoparticles was provided in several bacterial 
assay studies. To determine effective concentration against biofilm formation of 
P.aeruginosa, a crystal violet assay (CV assay) was developed (Figure 15). A kinetic 
growth assay was also provided to compare toxicity effects to inhibition. Comparing 
biofilm inhibition to growth inhibition can determine which concentrations of biofilm 
was inhibited where growth was not. It was determined fucose modified nanoparticles 
inhibit biofilm at 4.19 μM in our crystal violet endpoint assay (figure 15). Concentrations 
above 8.38 μM lead to growth inhibition in P.aeruginosa PAO1 (figure 16). A 18-fold 
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increase in potency is achieved compared to mono-galactose modified nanoparticles, 
which inhibit biofilm up to 75.8 μM.  
Concentrations of 25μL (8.38 μM) to 50μL (16.75 μM) of 100% with 100%-bis 
Fucose surface-modified nanoparticles was determined to inhibit growth of P. aeruginosa 
PAO1 by monitoring OD600 intensity. However, biofilm formation was inhibited at a 
concentration of 12.50 μL (4.19 μM) and concentrations of 4.19 μM and below provided 
growth in PAO1. Fucose surface-modified nanoparticles at a concentration of 4.19 μM 
with biofilm inhibition can be compared to 100% mono modified galactose nanoparticles 
biofilm inhibition concentration of 75.8 μM, which provides a 18-fold decrease in the 
concentration necessary to inhibit biofilm formation against P. aeruginosa.   
 
Figure 15. Inhibition of P. aeruginosa PAO1 biofilm formation based on the crystal 
violet assay. Surface-modified bis-Fucose-NP samples are described based on relative 
concentration of L-fucose on the nanoparticle surface. All data points are described as the 




Figure 16. Evaluation of P. aeruginosa PAO1 growth by monitoring OD600 with 100%-
bis-L-Fucose-surface-modified nanoparticles. No significant growth inhibition is 
observed with 100%-modified Fucose-NP at concentrations at or below 4.19 μM. Growth 
inhibition was noted at concentrations above two-fold higher at 16.75 μM. Error bars 
represent standard deviation of triplicate analysis. 
 
 
11. Discussion  
 Fucose modification on the surface of polymeric nanoparticles provides a 
distinctive binding interaction when compared to galactose. L-Fucose, specific to Lec-B 
binding, proves to be effective in inhibition of biofilm in preliminary bacterial assay 
studies with a minimum inhibition concentration of 4.19 μM. Bis-modification could be 
the cause for the decreased effective inhibition concentration, since a two-fold increase in 
the number of sugars is modifying the surface of the nanoparticle when compared to 
mono-modified galactose nanoparticles. A 18-fold increase in potency from our bis-
fucose modified nanoparticles could be compared to a 33-fold increase in potency seen in 
60% bis-modified galactose nanoparticles, which could provide evidence that our Lec-A 
targeted nanoparticles are more effective. However, nanoparticles could be precipitated in 
a 1:1 ratio with Lec-B and Lec-A specific surface modification or fucose and galactose 
41 
 
modification, respectively. Combination of lectin targeting could provide more effective 
specific targeting, increased potency and increased biofilm growth inhibition. 
12. Conclusion 
          Synthesis of Lec-B targeted nanoparticles proved to be more effective in achieving 
bis-modification when compared to Lec-A specific targeting for P. aeruginosa. However, 
future analogs could provide could provide to be more difficult as we approach tetra 
modified synthetic goals. Overall, a 4.19 μM biofilm inhibition concentration is a 







13. Materials and Methods 
13.1 General experimental. Unless otherwise noted, all reactions were performed in 
flame-dried glassware under an atmosphere of nitrogen or argon using dried reagents and 
solvents. All chemicals were purchased from commercial vendors and used without further 
purification. Anhydrous solvents were purchased from commercial vendors. 
Flash chromatography was performed using standard grade silica gel 60 230-400 mesh 
from SORBENT Technologies or using a Biotage Flash Purification system equipped with 
Biotage SNAP columns. All purifications were performed using gradients of mixtures of 
ethyl acetate and hexanes. Analytical thin-layer chromatography was carried out using 
Silica G TLC plates, 200 μm with UV254 fluorescent indicator (SORBENT Technologies), 
and visualization was performed by staining and/or absorbance of UV light.  
NMR spectra for small molecules were recorded using a Varian Mercury Plus 
spectrometer (400 MHz for 1H-NMR; 101 MHz for 13C-NMR). Chemical shifts are 
reported in parts per million (ppm) and were calibrated according to residual protonated 
solvent. Mass spectroscopy data was collected using an Agilent 1100-Series LC/MSD Trap 
LC-MS or a Micromass Quattromicro with a Waters 2795 Separations Module LC-MS 
with acetonitrile containing 0.1% formic acid as the mobile phase in positive ionization 
mode. Small molecule purity was determined on an Agilent 1100 series equipped with a 
Phenomenex Kinetex 2.6 µm C18-UPLC column using a gradient of water to acetonitrile 
with 0.1% TFA. 
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All final compounds were evaluated to be of greater than 90% purity by analysis of 
1H-NMR, 13C-NMR, and/or analytical HPLC.  
13.2 Synthesis of D-galactose-modified polymers. (2S,3R,4S,5S,6R)-6-
(acetoxymethyl) tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate, 2. D-galactose 
(5.00 g, 27.75 mmol) was dissolved in acetic acid (185 mL, 0.15 M) at room temperature. 
Acetyl bromide (16.40 mL, 222.02 mml) was added and the mixture was allowed to stir 
for 1 hour. The resulting solution was washed with toluene (2x, 40 mL), dried over 
sodium sulfate, and concentrated to dryness. The residue was purified by flash 
chromatography using a gradient of hexanes to EtOAc to provide (2S,3R,4S,5S,6R)-6-
(acetoxymethyl) tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate. Characterization data 
was consistent with a commercial sample of this compound. 
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-
((benzyloxy)carbonyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate, 4. 
(2S,3R,4S,5S,6R)-6-(acetoxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate, 2 (2 
g, 5.12 mmol) was dissolved in dichloromethane (10 mL, 0.5 M) at room temperature. 
Hydrobromic acid (33% in AcOH, 1.485 mL) and acetic acid (3.015 mL, 1.14 M) were 
added and the mixture was allowed to stir. After 30 minutes, the solution was diluted with 
50 mL of DCM, washed with sodium bicarbonate, dried with sodium sulfate, and 
concentrated to dryness. The residue (2 g) was re-dissolved in DCM (30 mL, 1.5 M) and 
treated with benzyl-4-hydroxybenzoate, 3 (2.34 g, 10.03 mmol), tetrabutylammonium 
hydrogensulfate (1.74 mg, 5.12 mmol), and 0.5 M sodium hydroxide (10 mL, 0.5 M). The 
biphasic mixture was allowed to stir overnight at room temperature, was diluted with DCM 
and acidified with 1M HCl, extracted with DCM (3 x 50mL), dried over Na2SO4, and 
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concentrated to dryness. The residue was purified by flash chromatography using a gradient 
of hexanes to EtOAc to provide (2R,3S,4S,5R,6S)-2- (acetoxymethyl)-6-(4-
((benzyloxy)carbonyl)phenoxy) tetrahydro-2H-pyran-3,4,5-triyl triacetate, 4 (1.006 g, 
1.848 mmol, 40.76%). 1H NMR (400 MHz, CDCl3) δ1H NMR (400 MHz, CDCl3) δ 7.96 
(d, J = 8.9 Hz, 2H), 7.40–7.22 (m, 5H), 6.95 (d, J = 8.4 Hz, 2H), 5.48–5.37 (m, 2H), 5.27 
(s, 2H), 5.11–5.01 (m, 2H), 4.20–3.95 (m, 3H), 2.11 (s, 3H), 1.98 (s, 6H), 1.94 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 170.44, 170.30, 170.19, 169.44, 165.88, 160.46, 136.19, 
131.84, 128.72, 128.37, 128.25, 125.14, 116.30, 98.93, 71.39, 70.84, 68.59, 66.93, 66.76, 
66.76, 61.50, 20.82, 20.79, 20.76, 20.69, 0.12. ESI-MS: predicted for C28H31O12 [M+H]+ 
559.544, observed, 559.569. 
4-(((2S,3R,4S,5S,6R)-3,4,5-triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)benzoic acid, 5. (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-
((benzyloxy)carbonyl)phenoxy)tetrahydro-2H- pyran-3,4,5-triyl triacetate, 4 (0.719 g, 
1.320 mmol) was dissolved in methanol (6.6 mL, 0.2 M) and palladium on carbon (10%, 
16 mg, 0.1 mmol) was added to the reaction flask at room temperature. Hydrogen was 
added via balloon and the reaction was stirred overnight at room temperature. The residue 
was separated by vacuum filtration washing with methanol to yield 4-(((2S,3R,4S,5S,6R)-
2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl) methoxy)benzoic acid, 
5 (571.2 mg, 1.219 mmol, 61.85%). 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 8.3 Hz, 
2H), 7.03 (d, J = 8.3 Hz, 2H), 5.57–5.43 (m, 2H), 5.20–5.07 (d, J = 51.1 Hz, 2H), 4.28–
4.06 (d, J = 84.7 Hz, 3H), 2.19 (s, 3H), 2.06 (s, 6H), 2.02 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 171.98, 171.91, 171.38, 171.22, 161.55, 132.97, 132.72, 117.02, 115.98, 99.36, 
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72.27, 72.16, 70.02, 68.67, 62.60, 49.00, 24.74, 20.69, 20.60, 20.54, 20.50, 20.49, 13.93. 
ESI-MS: predicted for C21H24O12Na [M+Na]+ 491.401, observed, 491.477. 
PS-b-PEG-Galactose, 1. To a room temperature solution of 4-(((2S,3R,4S,5S,6R)-
2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl) methoxy)benzoic acid, 
5 (20.5 mg, 0.068 mmol) in DMF (340uL) was added (Benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (30.1 mg, 0.068 mmol) and 
the mixture was allowed to stir for 5 minutes before the addition of PS-b-PEG-NH2 (150 
mg, 0.023 mmol, 6.6 kD, prepared from PS-b-PEG-OH as previously described [18]). The 
resulting solution was stirred at room temperature overnight. The reaction was quenched 
by the addition of water (1 mL) and EtOH (1 mL), and loaded into a 3.5 kD MWCO dialysis 
cassette (PierceTM Slide-A-LyzerTM G2, Thermo Scientific). The mixture was dialyzed into 
water for 12 h, at which time the dialysis cassette was transferred to a fresh solution of 
water and further dialyzed for an additional 12 h. After dialysis, the retained solution was 
lyopholyzed to provide PS-b-PEG-galactose, 1, as a white powder (153.6 mg, quantitative). 
The product was characterized by MALDI-MS (Bruker MicroFlex LFR MALDI-TOF) in 
positive linear detection mode using a matrix of dithranol:polymer of 1:1 evaporated from 
DCM onto a polished steel target. Collected spectra were analyzed with the Flex Analysis 
software (Bruker); the unmodified PS-b-PEG-NH2 was evaluated in the same manner as a 
standard. The observed m/z for PS-b-PEG-NH2 was 6212.07, and the observed m/z for PS-
b-PEG-galactose was 6501.40, consistent with complete polymer modification (anticipated 
Δ m/z for polymer modification = 282.24). 
13.3 Nanoparticle assembly. Nanoparticles with defined levels of surface 
modification were prepared through flash nanoprecipitation (FNP) as previously described 
46 
 
[18,19,39]. Briefly, PS, vitamin E (VitE), PS-b-PEG, PS-b-PEG-galactose, and/or PS-b-
PEG-mannose were dissolved at defined compositions in THF and rapidly micromixed 
with an equivalent volume of water within a confined impingement jet mixer, 
manufactured using HDPE (The Inventors Shop, Cinnaminson, NJ, USA), following the 
specifications provided [40], and diluted tenfold in a water collection bath. Particles with 
0–100%-surface-modification of galactose or mannose were prepared using defined 
combinations of PS-b-PEG/PS-b-PEG-galactose or PS-b-PEG-mannose. Vitamin E was 
used as the core bulking material in all NP formulations. Particle sizes were assessed with 
dynamic light scattering analysis (90Plus Particle Size Analyzer, Brookhaven Instruments 
Corporation). Size distributions were determined with backscattering measurements from 
658-nm illumination and displayed as intensity-weighted distributions; ‘particle diameter’ 
is the hydrodynamic diameter as calculated by DLS based on the Stokes Einstein equation 
using instrumental software. The composition of particles formed and particle size 
characterization data is provided in Table 1. 
13.4 Hemagglutination assay. The LecA-induced hemagglutination assay was 
performed as reported with modifications [20]. LecA (PA-IL) was purchased from Sigma-
Aldrich and used as received. Rabbit red blood cells (Innovative Research) at 100% were 
washed three times with 150 mM NaCl solution then diluted to 5% with NaCl (150 nM) 
solution. A hemocytometer was used to count the number of red blood cells that were in 
red blood cell solution and solutions were normalized to 2.94 x 1014 cells/mL. To find the 
minimal full hemagglutination inhibition concentration for LecA, a serial dilution was 
performed from a stock solution of 1 mg/ml LecA. Briefly, LecA (15 µl) was diluted into 
Tris buffer (Tris 20 µM, NaCl 100 mM, CaCl2 100 µM, pH = 7.5, 35 µl) in 96-well 
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microtiter V-bottom plates and was subjected to a two-fold serial dilution. Normalized 5% 
blood solution (10µl) was added to each well and incubated for 30 minutes at room 
temperature. After incubation, the plate was centrifuged for 1 minute at low rpm. The 
minimum full hemagglutination inhibition for LecA was found to be 1.2 µg/ml. Further 
analysis of inhibition of LecA-induced hemagglutination was performed with LecA at 
4xHU (4.8 µg/ml). Briefly, 25 µl of each nanoparticle formulation was subjected to a two-
fold serial dilution in Tris buffer and LecA was added to a final concentration of 4xHU. 
The plate was then incubated for 2 hours at room temperature. After incubation, normalized 
5% blood solution (10 µl) was added. The plate was then incubated for 30 minutes at room 
temperature and then centrifuged for 1 minute at low rpm before analysis. 
13.5 Crystal violet biofilm inhibition assay. The effect of inhibitors on static biofilm 
formation was evaluated using the crystal violet staining method with P. aeruginosa strain 
PAO1 [25] following the established procedure [41]. Briefly, overnight cultures of P. 
aeruginosa PAO1 were diluted 1:100 into fresh LB media. Compounds were added at the 
indicated concentrations in a 96-well microplate before static incubation at 37 C for 24 
hours. After incubation, the plates were thoroughly rinsed to remove planktonic cells and 
the adherent cells were quantified by staining with crystal violet and measurement of A550. 
The assay was performed with five replicates for each compound concentration. After 
exclusion of the highest and lowest absorbance readings the remaining triplicate readings 
were described as means with error bars representing standard deviations. 
13.6 Growth inhibition assay. The effect of nanoparticles on bacterial growth was 
evaluated with P. aeruginosa strain PAO1 [25]. Overnight cultures of P. aeruginosa PAO1 
were diluted 1:100 into fresh LB media. Nanoparticle formulations/compounds were added 
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at the indicated concentrations in a 96-well microplate. The plate was placed in a Molecular 
Devices SpectraMax i3x incubating plate reader set at 37 C with shaking. Measurement 
of A600 was recorded every 15 minutes for the duration of the experiment. Readings are 
reported as means with error bars representing the standard deviations of triplicate 
analyses. 
13.7 Fluorescent confocal microscopy. The effect of inhibitors on static biofilm 
formation was evaluated by confocal fluorescence microscopy with P. aeruginosa strain 
PA14 [25] following the established procedure [42]. Briefly, overnight cultures of PA14-
GFP [23] were diluted 1:100 into the designated media. Compounds were added at the 
indicated concentrations in 96-well microplates with optical grade glass bottoms 
(Corning) before static incubation at 37 C for 24 hours. After incubation, the samples 
were imaged on a Nikon Eclipse TI confocal microscope equipped with a 10X lens. 
Images were acquired from a central point in each well of the microplate. Each 
compound concentration was evaluated in duplicate. Image stacks were analyzed using 
Comstat2 [43, 44].  
13.8. Synthesis of tetra-galactose modified polymers.  
13.8.1 Mono-Boc diamine. p-xylyldiamine (0.200 g, 1.468 mmol) in DCM at 
0°C. triethylamine (0.500 mL, 3.5232 mmol) was added to cold solution. Next, a separate 
solution of di-tert-butyl pyrocarbonate (0.1282 g, 0.5873 mmol) in DCM was added to 
the first solution. This reaction was stirred overnight (18hrs) to room temperature (23°C). 
The reaction was converted in vacuum and redissolved in DCM (30mL) washed with 
bicarb, brine, dryed, concentrated. 7 (0.1318 g, 0.5577 mmol, 95%) 
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 13.8.2 Bis-Fmoc Lysine mono-boc linker. To a solution of bis-fmoc-L-lysine 
(2.499 g, 4.23 mmol) and mono-boc diamine 7 in DMF, N,N-diisopropylethylamine 
(3.55 mL, 20.30 mmol) and (Benzotriazol-1-yloxy) tripyrrolidinophosphonium 
hexafluorophosphate (2.64 g, 5.07 mmol) were added and reaction ran for 4 hours. 
Reaction was crashed out with water, the white solids were filtered, the white solids were 
then treated with Methanol and stirred overnight. Ten white solids were filtered out and 
were kept for further use. (1.8276 g, 2.259 mmol, 53.5%) 
 13.8.3 Bis-Galactose lysine mono-boc linker. To a solution of bis-fmoc lysine 
mono-boc linker (0.200 g, 0.2472 mmol) in DMF, 1,8-diazabicyclo[5.4.0]undec-7-ene 
(0.369 mL, 2.472 mmol) was added. This reaction was stirred at room temperature 
(23°C) for 30 minutes. Once done, the reaction was treated with 24 mL of diethyl ether 
and stirred for 5 minutes then placed into the freezer for 30 minutes. The supernatant was 
removed and the solids were concentrated and used crude (lysine mono-boc linker) 
without further purification. The crude product (0.2472 mmol) was made into a solution 
with DMF and modified D-galactose (0.2895 g, 0.6180 mmol) at room temperature 
(23°C). To this solution, N,N-diisopropylethylamine (0.2153 mL, 1.236 mmol) and 
(Benzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate (0.3216 g, 
0.6180 mmol) were added and stirred for 4 hours at room temperature (23°C). Once 
done, the reaction was quenched with water (50 mL) and vacuum filtered. The white 
solids were extracted and concentrated to yield product (0.292 g, 0.231 mmol, 93.4%) 
 13.8.4 Di-chlorotriazine PS-PEG (6.6 kD). To a solution of PS-PEG-OH (6.6 
kD) (0.1037 g, 0.01364 mmol) in DCM, trichorotriazine (0.0503 g, 0.2729 mmol) and 
N,N-diisopropylethylamine (0.006 mL, 0.03411 mmol) were added. The reaction ran for 
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48  hours at room temperature (23°C) and mixed by sonication. Roto-vaped to dryness 
and crashed out product with Diethyl Ether. Solids were filtered out to produce 
corresponding product(0.0876 g, 0.01296 mmol, 95%) 
 13.8.5 Tetra-galactose modified polymer. To a solution of bis-galactose modified 
lysine linker (0.1726 g, 0.1364 mmol) in DCM, hydrogen chloride, 4M in 1,4-dioxane 
(682 µL,) was added and the reaction was run overnight at room temperature (23°C). The 
reaction was concentrated giving product bis-galactose lysine linker and used crude 
without any further purification. The next step was to make a solution of previous 
product of bis-galactose lysine linker (crude, 0.01364 mmol) and di-chlorotriazine PS-
PEG (6.6 kD) (0.08766 g, 0.01296 mmol) in DCM. To this solution, N,N-
diisopropylethylamine (0.0010 mL, 0.05456 mmol) was added to the solution. This 
reaction was run at 70°C for 1 hour in the Microwave to produce product. 
13.8.6 Modified fucose benzyl-benzoate. To a solution of fucose-Br(OAc)3 (2.007 
g, 5.684 mmol) in DCM (34.1 mL, 1.5M) at 0°C, was added benzyl-4-hydroxylbenzoate 
(2.659 g, 11.652 mmol) and tetrabutylammonium hydrogensulfate (1.968 g, 5.798 mmol) 
stirring. 1M NaOH (11.4 mL, 0.5M) was added to form the biphasic mixture. After 72hrs 
the solution, now at room tempurature, was diluted with 30 mL of DCM, washed with 
water, brine, dried with sodium sulfate, and concentrated to dryness. A caramel consistant 
residue was purified using hexanes and ethyl acetate in a 100g column, where product 
elution occurred at 38% and elution of excess unreacted benzyl-4-hydroxylbenzoate 
eluted at 36-37%. Repurification was preformed at 10 column volumes over a generous 
gradient at 35-40%, elututing product in 20.6% yeild.  
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13.8.7 Modified fucose benzoate-acid. Fucose benzyl-benzoate (0.5717 g, 1.1746 
mmol) was dissolved in THF (5.7mL, 0.1 M) and palladium on hydroxide (12%, 68 mg) 
was added to the reaction flask at room temperature. Hydrogen was added via balloon 
and the reaction was stirred overnight at room temperature. The residue was separated by 
vacuum filtration with a thin layer of celite washing with THF to yield 76%. 
13.8.8 Bis-fucose-triacetate-boc-benzylamine-lysine. To a solution of bis-fmoc 
lysine mono-boc linker (0.160 g, 0.4746 mmol) in THF, 1,8-Diazabicyclo[5.4.0]undec-7-
ene (0.301 mL, 1.978 mmol) was added. This reaction was stirred at room temperature 
for 30 minutes. The reaction was treated with 10 mL of diethyl ether and stirred for 5 
minutes then placed into the freezer for 30 minutes. The supernatant was removed and 
the solids were concentrated and used crude (lysine mono-boc linker) without further 
purification. The crude product (0.1978 mmol) was made into a solution with DMF and 
modified L-fucose (0.1948 g, 0.4746 mmol) at room temperature. To this solution, N,N-
diisopropylethylamine (0.072 mL, 0.989 mmol) and (Benzotriazol-1-yloxy) 
tripyrrolidinophosphonium hexafluorophosphate (0.3216 g, 0.6180 mmol) were added 
and stirred for 4 hours at room temperature (23°C). Once done, the reaction was 
quenched with water (50 mL) and vacuum filtered. The white solids were extracted and 






13.9 H-NMR and C-NMR of Intermediates and Product 
 

















































Figure 21. H-NMR of tetra-benzoate-tetraactetate-galactose-bis-benzyldiamine-lysine on 
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